The Latest Cardiac and Vascular News
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into extension trial Safety profile was consistent with known […]
SAN MATEO, Calif., July 25, 2022 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of an investigator-initiated, multicenter SLIC study of its proprietary Monopoint® operating platform showing 82% first pass efficacy. Results from 33 consecutive patients also demonstrated 100% […]
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia’s new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the […]
MORRISVILLE, N.C., June 27, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in […]
MORRISVILLE, N.C., June 24, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to […]
MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July […]
– Secured access to new capital through debt and equity transactions – Increased utilization of Treprostinil Injection with increasing payer generic mandates – Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., May 12, 2022 […]
MORRISVILLE, N.C., April 25, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 35,700 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). Each stock option was granted as an inducement material […]
MORRISVILLE, N.C., April 18, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) today announced the closing of its previously announced underwritten public offering of 11,274,510 shares of its common stock, which includes full exercise of the underwriters’ over-allotment option to purchase 1,470,588 additional shares of common stock, at a public offering price of $5.10 […]
MORRISVILLE, N.C., April 12, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to […]
